{"id":56692,"date":"2026-02-09T21:41:09","date_gmt":"2026-02-09T13:41:09","guid":{"rendered":"https:\/\/flcube.com\/?p=56692"},"modified":"2026-02-09T21:41:09","modified_gmt":"2026-02-09T13:41:09","slug":"peijia-medical-files-ce-mark-for-geminione-teer-system-in-european-mitral-regurgitation-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56692","title":{"rendered":"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market"},"content":{"rendered":"\n<p><strong>Peijia Medical Ltd<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/9996:HKG\">HKG: 9996<\/a><\/strong>) announced it has <strong>submitted CE mark registration<\/strong> under the <strong>European Union Medical Device Regulation (EU MDR)<\/strong> for its <strong>GeminiOne transcatheter edge-to-edge repair (TEER) system<\/strong>, targeting the <strong>mitral regurgitation (MR)<\/strong> market in Europe. The filing advances Peijia&#8217;s <strong>global commercialization strategy<\/strong> alongside ongoing <strong>NMPA review in China<\/strong> and <strong>US early feasibility study approval<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Peijia Medical Ltd (HKG: 9996)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>GeminiOne \u2013 Transcatheter edge-to-edge repair (TEER) system<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Mitral regurgitation (MR)<\/td><\/tr><tr><td><strong>EU Filing<\/strong><\/td><td>CE mark application under EU MDR<\/td><\/tr><tr><td><strong>China Status<\/strong><\/td><td>NMPA registration accepted and under review<\/td><\/tr><tr><td><strong>US Status<\/strong><\/td><td>Early feasibility study (EFS) approved<\/td><\/tr><tr><td><strong>European Partner<\/strong><\/td><td>HighLife SAS (collaboration for EU market entry)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-design-innovation\">Technology Platform &amp; Design Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Device Class:<\/strong> <strong>Transcatheter edge-to-edge repair (TEER)<\/strong> \u2013 Minimally invasive mitral valve repair via cardiac catheterization<\/li>\n\n\n\n<li><strong>Key Differentiators:<\/strong><\/li>\n\n\n\n<li><strong>Smaller implant size<\/strong> vs. incumbent devices (Abbott MitraClip, Edwards Pascal)<\/li>\n\n\n\n<li><strong>Reduced delivery profile<\/strong> \u2013 Enables easier transseptal navigation and lower procedural complexity<\/li>\n\n\n\n<li><strong>Patented global design<\/strong> \u2013 Intellectual property protection across major markets<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Edge-to-edge leaflet approximation to create double-orifice mitral valve, reducing regurgitant volume<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-strategy\">Global Regulatory Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market<\/th><th>Status<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>European Union<\/strong><\/td><td>CE mark filing submitted (EU MDR)<\/td><td>Access to ~450 million population; premium pricing vs. China<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>NMPA registration under review<\/td><td>World&#8217;s largest MR patient population; domestic manufacturing advantage<\/td><\/tr><tr><td><strong>United States<\/strong><\/td><td>Early feasibility study approved<\/td><td>Pathway to pivotal trial and PMA submission; validation for global credibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-competitive-landscape\">Strategic Positioning &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Market Position<\/th><th>GeminiOne Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Abbott<\/strong><\/td><td>MitraClip<\/td><td>Global TEER leader (&gt;150,000 implants)<\/td><td>Smaller profile for complex anatomies<\/td><\/tr><tr><td><strong>Edwards Lifesciences<\/strong><\/td><td>Pascal<\/td><td>Second-generation TEER with independent grasping<\/td><td>Simpler delivery system, reduced procedure time<\/td><\/tr><tr><td><strong>Valcare Medical<\/strong><\/td><td>AMEND<\/td><td>Early-stage European player<\/td><td>Patent-protected design differentiation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HighLife Partnership:<\/strong> Collaboration with <strong>HighLife SAS<\/strong> leverages established <strong>European structural heart commercial infrastructure<\/strong>, accelerating hospital onboarding and reimbursement negotiations without building de novo EU sales force.<\/li>\n\n\n\n<li><strong>China-to-Global Expansion:<\/strong> Peijia&#8217;s <strong>dual-track regulatory approach<\/strong> (China NMPA + EU MDR + US EFS) mirrors successful <strong>medtech globalization strategies<\/strong> employed by MicroPort and Mindray, positioning GeminiOne as <strong>first Chinese TEER device<\/strong> with credible US\/EU pathway.<\/li>\n\n\n\n<li><strong>Mitral Regurgitation Market:<\/strong> Global TEER market projected to exceed <strong>$5 billion by 2030<\/strong>, driven by aging populations and <strong>expanding indications to functional MR<\/strong>; smaller-profile devices address <strong>unmet need in patients with challenging anatomy<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>EU MDR CE mark submission; NMPA review ongoing<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>CE mark approval (anticipated)<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Parallel<\/strong><\/td><td>US early feasibility study enrollment<\/td><td>2026<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>European commercial launch with HighLife<\/td><td>Post-CE mark<\/td><\/tr><tr><td><strong>Future<\/strong><\/td><td>US pivotal trial initiation; China NMPA approval<\/td><td>2027-2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding GeminiOne CE mark approval timelines, European commercial launch with HighLife, and Peijia Medical&#8217;s global TEER market penetration. Actual results may differ due to EU MDR review delays, competitive responses from Abbott and Edwards, and US pivotal trial enrollment challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020900086_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026020900086_c.\"><\/object><a id=\"wp-block-file--media-90be34c9-cf85-4634-8be0-90bfd747e042\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020900086_c.pdf\">2026020900086_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020900086_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-90be34c9-cf85-4634-8be0-90bfd747e042\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[1161,38,319],"class_list":["post-56692","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-hkg-9996","tag-market-approval-filings","tag-peijia-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European Union Medical Device Regulation (EU MDR) for its GeminiOne transcatheter edge-to-edge repair (TEER) system, targeting the mitral regurgitation (MR) market in Europe. The filing advances Peijia&#039;s global commercialization strategy alongside ongoing NMPA review in China and US early feasibility study approval.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56692\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market\" \/>\n<meta property=\"og:description\" content=\"Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European Union Medical Device Regulation (EU MDR) for its GeminiOne transcatheter edge-to-edge repair (TEER) system, targeting the mitral regurgitation (MR) market in Europe. The filing advances Peijia&#039;s global commercialization strategy alongside ongoing NMPA review in China and US early feasibility study approval.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56692\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T13:41:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56692#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56692\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market\",\"datePublished\":\"2026-02-09T13:41:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56692\"},\"wordCount\":478,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 9996\",\"Market approval filings\",\"Peijia Medical\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56692#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56692\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56692\",\"name\":\"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-09T13:41:09+00:00\",\"description\":\"Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European Union Medical Device Regulation (EU MDR) for its GeminiOne transcatheter edge-to-edge repair (TEER) system, targeting the mitral regurgitation (MR) market in Europe. The filing advances Peijia's global commercialization strategy alongside ongoing NMPA review in China and US early feasibility study approval.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56692#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56692\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56692#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market - Insight, China&#039;s Pharmaceutical Industry","description":"Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European Union Medical Device Regulation (EU MDR) for its GeminiOne transcatheter edge-to-edge repair (TEER) system, targeting the mitral regurgitation (MR) market in Europe. The filing advances Peijia's global commercialization strategy alongside ongoing NMPA review in China and US early feasibility study approval.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56692","og_locale":"en_US","og_type":"article","og_title":"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market","og_description":"Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European Union Medical Device Regulation (EU MDR) for its GeminiOne transcatheter edge-to-edge repair (TEER) system, targeting the mitral regurgitation (MR) market in Europe. The filing advances Peijia's global commercialization strategy alongside ongoing NMPA review in China and US early feasibility study approval.","og_url":"https:\/\/flcube.com\/?p=56692","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T13:41:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56692#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56692"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market","datePublished":"2026-02-09T13:41:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56692"},"wordCount":478,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 9996","Market approval filings","Peijia Medical"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56692#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56692","url":"https:\/\/flcube.com\/?p=56692","name":"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-09T13:41:09+00:00","description":"Peijia Medical Ltd (HKG: 9996) announced it has submitted CE mark registration under the European Union Medical Device Regulation (EU MDR) for its GeminiOne transcatheter edge-to-edge repair (TEER) system, targeting the mitral regurgitation (MR) market in Europe. The filing advances Peijia's global commercialization strategy alongside ongoing NMPA review in China and US early feasibility study approval.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56692#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56692"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56692#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56692"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56692\/revisions"}],"predecessor-version":[{"id":56694,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56692\/revisions\/56694"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}